Global Pharmaceuticals: exploring a rapidly evolving marketplace
As the US policy overhang has subsided, pharmaceutical companies face a shifting set of risks and opportunities. In this webinar, analysts provided an updated global pharmaceutical sector outlook, with a focus on how innovation trends and emerging sales channels are shaping credit profiles. They also discussed the evolving M&A landscape as companies further aim to mitigate patent expirations and regulatory pricing pressures, while re-positioning portfolios for the next phase of growth.
Discussion topics included:
- Key earnings growth drivers in 2026-2027 across branded pharma, with a focus on the GLP-1 market opportunity juxtaposed against escalating pricing pressures.
- A detailed look at industrywide patent risks that will peak in 2028-2029, while conversely highlighting the growth opportunity for biosimilars and generics.
- Our M&A outlook for 2026, including the possibility of larger & transformative deals.
- A closer look at the implications from MFN pricing deals, including the rising advent of the direct-to-consumer channel.
Speakers
Ola Hannoun-Costa
Associate Managing Director, Corporate Finance
Moody’s Ratings
Michael Weinstein
Vice President- Senior Credit Officer
Moody’s Ratings
Michael Levesque
Senior Vice President
Moody's Ratings
Marie Fischer-Sabatié
Senior Vice President, Corporate Finance
Moody's Ratings
Francesco Bozzano
Vice President, Corporate Finance
Moody's Ratings
Gilberto Ramos
Assistant Vice President-Analyst, Corporate Finance
Moody’s Ratings
Tobias Wagner
Executive Director, Corporate Finance Group
Moody’s Ratings
Confirm cancellation
An error occurred trying to play the stream. Please reload the page and try again.
Close